Skip to content

Our pipeline

We have an in-house drug discovery pipeline, and out-license novel targets and indication extension assets to partners for co-development

Biopharma pipeline

As well as identifying multiple targets that feature in biopharma development portfolios, our pipeline includes novel drug targets with genetic linkage and repositioning opportunities at all stages of development. All assets in our pipeline include patient stratification biomarkers and are available for partnering.

Therapeutic area
Indication
Patient stratification biomarkers
Novel targets
Repositioning opportunities
Active molecules
In vitro hit validation
In vivo hit validation
Ageing
Osteoarthritis
Autoimmune
Rheumatoid Arthritis 

See more

See less

High-resolution patient stratification results:

  • 520 Disease risk loci
  • 250 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 57 Known active compounds
Download poster
Autoimmune
Sjögren’s syndrome 

See more

See less

High-resolution patient stratification results:

  • 717 Disease risk loci
  • 299 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 263 Known active compounds
Learn more
Cardiovascular
Atrial fibrillation
Cardiovascular
Cardiovascular disease
Infectious
COVID-19

See more

See less

High-resolution patient stratification results:

  • 158 Disease risk loci
  • 88 Risk associated genes mapped to disease associated mechanisms
  • 23 Druggable targets
  • 59 Known active compounds
Learn more
Metabolic
Diabetes type 2 complications

See more

See less

High-resolution patient stratification results:

  • 35 Disease risk loci
  • 20 Risk associated genes mapped to disease associated mechanisms
  • 8 Druggable targets
  • 120 Known active compounds
Learn more
Neurological
ALS

See more

See less

High-resolution patient stratification results:

  • 73 Disease risk loci
  • 30 Risk associated genes mapped to disease associated mechanisms
  • 16 Druggable targets
  • 19 Known active compounds
Learn more
Neurological
Alzheimer's disease

See more

See less

High-resolution patient stratification results:

  • 267 Disease risk loci
  • 113 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 732 Known active compounds
Learn more
Neurological
Migraine
Neurological
Parkinson's disease 

See more

See less

High-resolution patient stratification results:

  • 707 Disease risk loci
  • 341 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 2611 Known active compounds
Download poster
Neuropsychiatric
Schizophrenia 

See more

See less

High-resolution patient stratification results:

  • 125 Disease risk loci
  • 85 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 155 Known active compounds
Learn more
Respiratory
Asthma
(non-T2) 

See more

See less

High-resolution patient stratification results:

  • 570 Disease risk loci
  • >200 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 281 Known active compounds
Learn more
Respiratory
Asthma
(T2-high) 
Respiratory
COPD 

See more

See less

High-resolution patient stratification results:

  • 359 Disease risk loci
  • 163 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • >300 Known active compounds
Download poster
Women’s health
Endometriosis 

See more

See less

High-resolution patient stratification results:

  • 233 Disease risk loci
  • 136 Risk associated genes mapped to disease associated mechanisms
  • >30 Druggable targets
  • 74 Known active compounds
Learn more

Last updated June 30, 2022

Indication extensions

We have identified hundreds of indication extension opportunities across all stages of development. These licensable assets have high market value and strong efficacy potential for repositioning into new disease areas using patient stratification biomarkers to match them to clinically relevant patient subgroups.

Therapeutic area
Indication
Repositioning opportunities
Preclinical
Phase 1
Phase 2
Phase 3
Marketed
Autoimmune
Rheumatoid Arthritis
12
4
4
1
1
2
Autoimmune
Inflammatory bowel disease
4
1
1
1
1
Cardiovascular
Cardiovascular disease
3
2
1
Autoimmune
Sjögren’s syndrome
6
1
1
1
3
Infectious
COVID-19
31
4
5
8
4
10
Metabolic
Diabetes type 2 complications
6
2
1
2
1
Neurological
ALS
20
3
4
4
1
8
Neurological
Alzheimer's disease
8
1
4
1
1
1
Neurological
Migraine
9
3
1
2
1
2
Neurological
Parkinson's disease
36
6
6
9
9
6
Neuropsychiatric
Schizophrenia
6
2
1
3
Respiratory
Asthma (non-T2)
5
1
1
2
1
Respiratory
Asthma (T2-high)
12
3
2
2
4
1
Respiratory
COPD
11
4
2
1
4
Women’s health
Endometriosis
51
9
10
14
5
13

Last updated June 26, 2022

Upcoming innovation

We are running new disease studies all the time, adding two new chronic disease indications to our DiseaseBank every month. Contact us to talk about your priorities and discuss partnering opportunities in one of our current or upcoming disease studies.

Partner with us
  • arr-up Alopecia
  • arr-up Vitiligo
  • arr-up Age-related macular degeneration
  • arr-up Biopolar disorder
  • arr-up Chronic fatigue syndrome / ME
  • Inflammatory bowel disease
  • Interstitial pulmonary fibrosis
  • Asthma COPD overlap syndrome
  • Uterine fibroids
  • Prostate cancer
  • Glaucoma

Please view our pipelines on a larger screen or device for the best experience.

pipeline-img